- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 8, 2024Tara Sutton, Emily Tremblay Shortlisted for Euromoney’s Women in Business Law Awards
-
April 24, 2024IP Leadership Executive Summit
-
April 24, 2024IP Odyssey: Navigating the Latest Developments in Intellectual Property Law
-
April 30, 2024Navigating Generational Dynamics
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Winter 2015
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Altergon SA v. Actavis Labs. UT, Inc., 15-0883 (D. Del.) | Oct. 1, 2015 | Hon. Richard G. Andrews | Flector® (diclofenac epolamine patch) | 5,607,690 |
| Alcon Pharms. Ltd. v. Par Pharm., Inc., 15-7240 (D.N.J.) | Oct. 1, 2015 | Hon. Peter G. Sheridan | Ciprodex® (ciprofloxacin / dexamethasone otic suspension) |
6,284,804
6,359,016
|
| Amerigen Pharms. Ltd. v. Shire LLC, IPR2015-02009 (PTAB) | Oct. 1, 2015 | N/A | Adderall XR® (amphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate extended-release capsules) | RE42,096 |
| Steadymed Ltd. v. United Therapeutics Corp., IPR2016-00006 (PTAB) | Oct. 2, 2015 | N/A |
Remodulin® (treprostinil for injection)
Tyvaso® (treprostinil solution)
Orenitram® (treprostinil diolamine extended-release tablets)
|
8,497,393 |
| Actavis Labs. UT, Inc. v. Par Pharm., Inc., 15-0886 (D. Del.) | Oct. 2, 2015 | Hon. Leonard P. Stark | Gelnique® (oxybutynin chloride gel) |
7,029,694
7,179,483
8,241,662
8,920,392
|
| AbbVie Inc. v. Hetero USA Inc., 15-0889 (D. Del.) | Oct. 2, 2015 | Hon. Richard G. Andrews | Kaletra® (lopinavir / ritonavir tablets) |
6,037,157
6,703,403
7,148,359
7,364,752
8,025,899
8,268,349
8,399,015
8,309,613
8,377,952
8,470,347
8,691,878
|
| Lupin Ltd. v. Daiichi Sankyo Co., Ltd., IPR2015-01881 (PTAB) | Oct. 5, 2015 | N/A | Effient® (prasugrel hydrochloride tablets) | 8,569,325 |
| Lupin Ltd. v. Daiichi Sankyo Co., Ltd., IPR2015-01882 (PTAB) | Oct. 5, 2015 | N/A | Effient® (prasugrel hydrochloride tablets) | 8,404,703 |
| Par Pharm., Inc. v. Jazz Pharms., Inc., IPR2016-00002 (PTAB) | Oct. 6, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 8,772,306 |
| Ranbaxy Inc. v. Jazz Pharms., Inc., IPR2016-00024 (PTAB) | Oct. 7, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 8,772,306 |
| Merck & CIE v. Lupin Ltd., 15-0899 (D. Del.) | Oct. 8, 2015 | Hon. Richard G. Andrews | Beyaz® (drospirenone / 17α-ethinylestradiol / levomefolate calcium tablets) | 6,441,168 |
| Salix Pharms., Inc. v. Taro Pharms. USA, Inc., 15-0900 (D. Del.) | Oct. 8, 2015 | Hon. Sue L. Robinson | Moviprep® (ascorbic acid / polyethylene glycol 3350 / potassium chloride / sodium ascorbate / sodium chloride / sodium sulfate oral solution) |
7,169,381
7,658,914
|
| Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC, 15-7378 (D.N.J.) | Oct. 8, 2015 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride for injection) |
7,947,724
8,518,981
8,598,218
9,066,980
9,125,905
|
| Bayer Intellectual Property GmbH v. Aurobindo Pharma Ltd., 15-0902 (D. Del.) | Oct. 9, 2015 | Hon. Sue L. Robinson | Xarelto® (rivaroxaban tablets) |
7,157,456
7,585,860
7,592,339
|
| Forest Labs., LLC v. Accord Healthcare, Inc., 15-0903 (D. Del.) | Oct. 9, 2015 | Hon. Leonard P. Stark | Namenda® XR (memantine hydrochloride extended-release tablets) |
8,039,009
8,168,209
8,173,708
8,283,379
8,329,752
8,362,085
8,598,233
|
| Unimed Pharms., LLC v. Lupin Atlantis Holdings SA, 15-0904 (D. Del.) | Oct. 9, 2015 | Hon. Richard G. Andrews | AndroGel® (testosterone gel) |
6,503,894
8,466,136
8,466,137
8,466,138
8,486,925
8,729,057
8,741,881
8,754,070
8,759,329
9,125,816
9,132,089
|
| Novartis Pharms. Corp. v. Roxane Labs., Inc., 15-0908 (D. Del.) | Oct. 9, 2015 | Hon. Leonard P. Stark | Gleevec® (imatinib mesylate tablets) |
6,894,051
RE43,932
|
| AstraZeneca AB v. Teva Pharms. USA, Inc., 15-0909 (D. Del.) | Oct. 9, 2015 | Hon. Gregory M. Sleet | Kombiglyze™ XR (saxagliptin hydrochloride / metformin hydrochloride extended-release tablets) | 8,628,799 |
| AstraZeneca AB v. Zydus Pharms. (USA) Inc., 15-7415 (D.N.J.) | Oct. 9, 2015 | Hon. Mary L. Cooper | Nexium® (esomeprazole magnesium delayed-release tablets) |
6,369,085
7,411,070
8,466,175
|
| Salix Pharms., Inc. v. Taro Pharms. USA, Inc., 15-7980 (S.D.N.Y.) | Oct. 9, 2015 | Hon. Vernon S. Broderick | Moviprep® (ascorbic acid / polyethylene glycol 3350 / potassium chloride / sodium ascorbate / sodium chloride / sodium sulfate oral solution) |
7,169,381
7,658,914
|
| Flamel Ireland, Ltd. v. Mylan Pharms. Inc., 15-0178 (N.D.W.V.) | Oct. 9, 2015 | Hon. Irene M. Keeley | Coreg CR® (carvedilol phosphate extended-release capsules) | 8,101,209 |
| Agila Specialties Inc. f/k/a Strides Inc. v. Cephalon, Inc., IPR2016-00026 (PTAB) | Oct. 9, 2015 | N/A | Treanda® (bendamustine hydrochloride for infusion) | 8,791,270 |
| Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC, 15-0918 (D. Del.) | Oct. 13, 2015 | Hon. Gregory M. Sleet | Aloxi® (palonosetron hydrochloride for injection) |
7,947,724
8,518,981
8,598,218
9,066,980
9,125,905
|
| Vanda Pharms. Inc. v. Roxane Labs., Inc., 15-0919 (D. Del.) | Oct. 13, 2015 | Hon. Gregory M. Sleet | Fanapt® (iloperidone tablets) | 9,138,432 |
| Vanda Pharms. Inc. v. Taro Pharms. USA, Inc., 15-0920 (D. Del.) | Oct. 13, 2015 | Hon. Gregory M. Sleet | Fanapt® (iloperidone tablets) |
8,586,610
9,138,432
|
| Vanda Pharms. Inc. v. Inventia Healthcare Pvt. Ltd., 15-0921 (D. Del.) | Oct. 13, 2015 | Hon. Gregory M. Sleet | Fanapt® (iloperidone tablets) | 9,138,432 |
| Vanda Pharms. Inc. v. Apotex Inc., 15-0922 (D. Del.) | Oct. 13, 2015 | Hon. Gregory M. Sleet | Fanapt® (iloperidone tablets) |
8,586,610
9,138,432
|
| Boehringer Ingelheim Pharma GmbH & Co. KG v. Sandoz Inc., 15-7461 (D.N.J.) | Oct. 13, 2015 | Hon. Noel L. Hillman | Aggrenox® (dipyridamole / acetylsalicylic acid extended-release capsules) | 6,015,577 |
| Novartis Pharms. Corp. v. Roxane Labs., Inc., 15-2905 (S.D. Ohio) | Oct. 13, 2015 | Hon. Edmund A Sargus | Gleevec® (imatinib mesylate tablets) |
6,894,051
RE43,932
|
| AstraZeneca Pharms. LP v. Mylan Pharms. Inc., 15-0183 (N.D.W.V.) | Oct. 15, 2015 | Hon. Irene M. Keeley | Faslodex® (fulvestrant injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
| Neptune Generics, LLC v. AstraZeneca PLC., IPR2016-00049 (PTAB) | Oct. 15, 2015 | N/A | Movantik® (naloxegol oxalate tablets) | 7,786,133 |
| Purdue Pharma L.P. v. Alvogen Pine Brook, Inc., 15-0940 (D. Del.) | Oct. 16, 2015 | Hon. Gregory M. Sleet | Hysingla® ER (hydrocodone bitartrate extended-release tablets) |
9,084,816
9,095,614
9,095,615
|
| Fresenius Kabi USA, LLC v. Mylan Labs. Ltd., 15-0942 (D. Del.) | Oct. 19, 2015 | Hon. Leonard P. Stark | Naropin® (ropivacaine hydrochloride for injection) |
7,828,787
7,857,802
8,118,802
8,162,915
|
| Jazz Pharms., Inc. v. Par Pharm., Inc., 15-7580 (D.N.J.) | Oct. 19, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 9,050,302 |
| Otsuka Pharm. Co., Ltd. v. Aurobindo Pharma Ltd., 15-7584 (D.N.J.) | Oct. 19, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
| Horizon Therapeutics, Inc. v. Lupin Ltd., 15-7624 (D.N.J.) | Oct. 19, 2015 | Hon. Robert B. Kugler | Ravicti® (glycerol phenylbutyrate oral liquid) |
8,404,215
8,642,012
9,095,559
|
| Fresenius Kabi USA, LLC v. Mylan Labs. Ltd., 15-0185 (N.D.W.V.) | Oct. 19, 2015 | Hon. Irene M. Keeley | Naropin® (ropivacaine hydrochloride for injection) |
7,828,787
7,857,802
8,118,802
8,162,915
|
| Alcon Pharms. Ltd. v. Akorn, Inc., 15-0948 (D. Del.) | Oct. 21, 2015 | Hon. Sue L. Robinson | Vigamox® (moxifloxacin hydrochloride ophthalmic solution) |
6,716,830
7,671,070
|
| Takeda Pharm. Co. Ltd. v. Aurobindo Pharma Ltd., 15-7635 (D.N.J.) | Oct. 21, 2015 | Hon. Mary L. Cooper | Prevacid® SoluTab™ (lansoprazole delayed-release orally disintegrating tablets) |
6,328,994
7,431,942
7,875,292
7,399,485
|
| Pfizer Inc. v. Mylan Inc., 15-0960 (D. Del.) | Oct. 22, 2015 | Hon. Sue L. Robinson | Tygacil® (tigecycline injectable IV infusion) |
7,879,828
8,372,995
8,975,242
|
| Unimed Pharms., LLC v. Amneal Pharms., LLC, 15-0964 (D. Del.) | Oct. 23, 2015 | Hon. Richard G. Andrews | AndroGel® (testosterone gel) |
6,503,894
8,729,057
8,741,881
8,754,070
8,759,329
9,125,816
9,132,089
|
| Forest Labs., LLC v. Amerigen Pharms., Inc., 15-0966 (D. Del.) | Oct. 23, 2015 | Hon. Leonard P. Stark | Namzaric® (memantine hydrochloride / donepezil hydrochloride extended-release capsules) |
8,039,009
8,058,291
8,168,209
8,173,708
8,283,379
8,293,794
8,329,752
8,338,485
8,338,486
8,362,085
8,580,858
8,598,233
|
| Tris Pharma, Inc. v. Actavis Labs. FL, Inc., 15-0969 (D. Del.) | Oct. 23, 2015 | Hon. Gregory M. Sleet | Quillivant XR® (methylphenidate hydrochloride extended-release oral suspension) | 9,040,083 |
| Takeda Pharm. Co. Ltd. v. Aurobindo Pharma Ltd., 15-9398 (N.D. Ill.) | Oct. 23, 2015 | Hon. Charles P. Kocoras | Prevacid® SoluTab™ (lansoprazole delayed-release orally disintegrating tablets) |
6,328,994
7,431,942
7,875,292
7,399,485
|
| Tris Pharma, Inc. v. Actavis Labs. FL, Inc., 15-7684 (D.N.J.) | Oct. 23, 2015 | Hon. Claire C. Cecchi | Quillivant XR® (methylphenidate hydrochloride extended-release oral suspension) | 9,040,083 |
| Mallinckrodt LLC v. Par Pharm. Inc., 15-7694 (D.N.J.) | Oct. 23, 2015 | Hon. Katharine S. Hayden | Xartemis XR® (oxycodone hydrochloride / acetaminophen extended-release tablets) |
6,488,962
8,597,681
8,658,631
8,741,885
8,980,319
8,992,975
7,976,870
8,668,929
8,372,432
8,377,453
8,394,408
9,050,335
|
| Pfizer Inc. v. Mylan Inc., 15-0188 (N.D.W.V.) | Oct. 23, 2015 | Hon. Irene M. Keeley | Tygacil® (tigecycline injectable IV infusion) |
7,879,828
8,372,995
8,975,242
|
| Novartis AG v. Apotex Inc., 15-0975 (D. Del.) | Oct. 26, 2015 | Hon. Leonard P. Stark | Gilenya® (fingolimod capsules) | 5,604,229 |
| Par Pharm., Inc. v. Novartis AG, IPR2016-00074 (PTAB) | Oct. 26, 2015 | N/A | Afinitor® (everolimus tablets) | 7,741,338 |
| Par Pharm., Inc. v. Novartis AG, IPR2016-00075 (PTAB) | Oct. 26, 2015 | N/A | Afinitor® (everolimus tablets) | 7,297,703 |
| Par Pharm., Inc. v. Novartis AG, IPR2016-00078 (PTAB) | Oct. 26, 2015 | N/A | Zortress® (everolimus tablets) | 6,455,518 |
| Par Pharm., Inc. v. Novartis AG, IPR2016-00084 (PTAB) | Oct. 26, 2015 | N/A | Zortress® (everolimus tablets) | 5,665,772 |
| Complex Innovations, LLC v. Amgen Inc., IPR2016-00085 (PTAB) | Oct. 26, 2015 | N/A | Sensipar® (cinacalcet hydrochloride tablets) | 7,829,595 |
| Noven Pharms., Inc. v. Mylan Technologies Inc., 15-0979 (D. Del.) | Oct. 27, 2015 | Hon. Leonard P. Stark | Daytrana® (methylphenidate transdermal system) |
6,210,705
6,348,211
8,632,802
9,034,370
|
| Horizon Pharma Ireland Ltd. v. Actavis Labs. UT, Inc., 15-7742 (D.N.J.) | Oct. 27, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
9,168,304
9,168,305
|
| Horizon Pharma Ireland Ltd. v. Amneal Pharms. LLC, 15-7743 (D.N.J.) | Oct. 27, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
9,168,304
9,168,305
|
| Horizon Pharma Ireland Ltd. v. IGI Labs., Inc., 15-7744 (D.N.J.) | Oct. 27, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
9,168,304
9,168,305
|
| Horizon Pharma Ireland Ltd. v. Lupin Ltd., 15-7745 (D.N.J.) | Oct. 27, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
9,168,304
9,168,305
|
| Novartis Pharms. Corp. v. Amneal Pharms. LLC, 15-0986 (D. Del.) | Oct. 28, 2015 | Hon. Leonard P. Stark | Gleevec® (imatinib mesylate tablets) |
6,894,051
RE43,932
|
| Novartis Pharms. Corp. v. Natco Pharma Ltd., 15-0987 (D. Del.) | Oct. 28, 2015 | Hon. Leonard P. Stark | Gleevec® (imatinib mesylate tablets) |
6,894,051
RE43,932
|
| Novartis AG v. Apotex Inc., 15-62273 (S.D. Fla.) | Oct. 28, 2015 | Hon. Beth Bloom | Gilenya® (fingolimod capsules) | 5,604,229 |
| Fresenius Kabi USA, LLC v. Cephalon, Inc., IPR2016-00098 (PTAB) | Oct. 28, 2015 | N/A | Treanda® (bendamustine hydrochloride for infusion) | 8,791,270 |
| Novartis Pharms. Corp. v. Natco Pharma Ltd., 15-8534 (S.D.N.Y.) | Oct. 29, 2015 | Hon. Andrew L. Carter, Jr, | Gleevec® (imatinib mesylate tablets) |
6,894,051
RE43,932
|
| Noven Pharms., Inc. v. Mylan Technologies Inc., 15-0194 (N.D.W.V.) | Oct. 29, 2015 | Hon. Irene M. Keeley | Daytrana® (methylphenidate transdermal system) |
6,210,705
6,348,211
8,632,802
9,034,370
|
| Orexo AB v. Actavis Elizabeth LLC, 15-0996 (D. Del.) | Oct. 30, 2015 | Hon. Sue L. Robinson | Zubsolv® (buprenorphine hydrochloride / naloxone hydrochloride tablets) |
8,454,996
8,940,330
|
| AstraZeneca LP v. Mylan Inc., 15-0999 (D. Del.) | Oct. 30, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
6,251,910
6,525,060
7,250,419
7,265,124
8,425,934
|
| AstraZeneca LP v. Sigmapharm Labs., LLC, 15-1000 (D. Del.) | Oct. 30, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
6,251,910
6,525,060
7,250,419
7,265,124
8,425,934
|
| AstraZeneca LP v. InvaGen Pharms. Inc., 15-1001 (D. Del.) | Oct. 30, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
6,251,910
6,525,060
7,250,419
7,265,124
8,425,934
|
| AstraZeneca LP v. Watson Labs., Inc., 15-1002 (D. Del.) | Oct. 30, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) | 8,425,934 |
| AstraZeneca LP v. Alembic Pharms. Ltd., 15-1003 (D. Del.) | Oct. 30, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) | 8,425,934 |
| Otsuka Pharm. Co., Ltd. v. Zydus Pharms. USA Inc., 15-7802 (D.N.J.) | Oct. 30, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
| Otsuka Pharm. Co., Ltd. v. Amneal Pharms. LLC, 15-7803 (D.N.J.) | Oct. 30, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
| AstraZeneca LP v. InvaGen Pharms. Inc, 15-6282 (E.D.N.Y.) | Nov. 2, 2015 | Hon. Kiyo A. Matsumoto | Brilinta® (ticagrelor tablets) |
6,251,910
6,525,060
7,250,419
7,265,124
8,425,934
|
| Innopharma Licensing, Inc. v. Senju Pharm. Co., Ltd., IPR2016-00089 (PTAB) | Nov. 2, 2015 | N/A | Prolensa® (bromfenac sodium ophthalmic solution) | 8,754,131 |
| Innopharma Licensing, Inc. v. Senju Pharm. Co., Ltd., IPR2016-00090 (PTAB) | Nov. 2, 2015 | N/A | Prolensa® (bromfenac sodium ophthalmic solution) | 8,871,813 |
| Innopharma Licensing, Inc. v. Senju Pharm. Co., Ltd., IPR2016-00091 (PTAB) | Nov. 2, 2015 | N/A | Prolensa® (bromfenac sodium ophthalmic solution) | 8,927,606 |
| Fresenius Kabi USA, LLC v. Cephalon, Inc., IPR2016-00111 (PTAB) | Nov. 2, 2015 | N/A | Treanda® (bendamustine hydrochloride for infusion) | 8,895,756 |
| AstraZeneca LP v. Sigmapharm Labs., LLC, 15-5948 (E.D. Pa.) | Nov. 2, 2015 | Hon. Gerald A. McHugh | Brilinta® (ticagrelor tablets) |
6,251,910
6,525,060
7,250,419
7,265,124
8,425,934
|
| AstraZeneca LP v. Mylan In., LLC, 15-0202 (N.D.W.V.) | Nov. 2, 2015 | Hon. Irene M. Keeley | Brilinta® (ticagrelor tablets) |
6,251,910
6,525,060
7,250,419
7,265,124
8,425,934
|
| Purdue Pharma L.P. v. Actavis Labs. FL, Inc., 15-1008 (D. Del.) | Nov. 3, 2015 | Hon. Gregory M. Sleet | Hysingla® ER (hydrocodone bitartrate extended-release tablets) |
9,056,052
9,060,940
9,084,816
9,095,614
|
| Boehringer Ingelheim Pharma Gmbh & Co. KG v. Apotex Corp., 15-7880 (D.N.J.) | Nov. 3, 2015 | Hon. Mary L. Cooper | Pradaxa® ER (dabigatran etexilate mesylate capsules) | 6,087,380 |
| AstraZeneca Pharms. LP v. Teva Pharms. USA, Inc., 15-7889 (D.N.J.) | Nov. 3, 2015 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
| AstraZeneca LP v. Sandoz Inc., 15-1012 (D. Del.) | Nov. 4, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) | 8,425,934 |
| AstraZeneca LP v. Micro Labs Ltd., 15-1013 (D. Del.) | Nov. 4, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) | 8,425,934 |
| Indivior Inc. v. Mylan Technologies Inc., 15-1016 (D. Del.) | Nov. 4, 2015 | Hon. Richard G. Andrews | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) |
8,475,832
8,017,150
8,603,514
|
| Warner Chilcott Co., LLC v. Mylan Pharms. Inc., 15-7882 (D.N.J.) | Nov. 4, 2015 | Hon. Mary L. Cooper | Minastrin® 24 Fe (ethinyl estradiol / norethindrone acetate / ferrous fumarate tablets) | 6,667,050 |
| Novartis Pharms. Corp. v. Amneal Pharms. LLC, 15-1025 (D. Del.) | Nov. 5, 2015 | Hon. Richard G. Andrews | Exelon® Patch (rivastigmine transdermal system or extended release film) |
6,316,023
6,335,031
|
| Novartis Pharms. Corp. v. Dr. Reddy’s Labs, Ltd., 15-1026 (D. Del.) | Nov. 5, 2015 | Hon. Richard G. Andrews | Exelon® Patch (rivastigmine transdermal system or extended release film) |
6,316,023
6,335,031
|
| Takeda Gmbh v. Micro Labs USA, Inc., 15-7921 (D.N.J.) | Nov. 5, 2015 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) | 5,712,298 |
| Dow Pharm. Sciences, Inc. v. Tolmar, Inc., 15-7971 (D.N.J.) | Nov. 5, 2015 | Hon. Stanley R. Chesler | Acanya® (clindamycin phosphate / benzoyl peroxide gel) |
8,288,434
8,663,699
|
| Indivior Inc. v. Mylan Technologies Inc., 15-0209 (N.D.W.V.) | Nov. 5, 2015 | Hon. Irene M. Keeley | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) |
8,475,832
8,017,150
8,603,514
|
| Dow Pharm. Sciences, Inc. v. Tolmar, Inc., 15-1030 (D. Del.) | Nov. 6, 2015 | Hon. Gregory M. Sleet | Acanya® (clindamycin phosphate / benzoyl peroxide gel) |
8,288,434
8,663,699
|
| Allergan Sales, LLC v. Aurobindo Pharma Ltd., 15-1032 (D. Del.) | Nov. 6, 2015 | Hon. Leonard P. Stark | Acular LS® (ketorolac tromethamine ophthalmic solution) |
8,008,338
8,207,215
8,377,982
8,541,463
8,648,107
8,906,950
8,946,281
|
| Purdue Pharma L.P. v. Collegium Pharm., Inc., 15-13783 (D. Mass.) | Nov. 6, 2015 | Hon. F. Dennis Saylor, IV |
OxyContin® (oxycodone extended-release tablets)
Xtampza ER™ (oxycodone extended-release capsules)
|
9,073,933 |
| Novartis Pharms. Corp. v. Dr. Reddy’s Labs, Ltd., 15-7964 (D.N.J.) | Nov. 6, 2015 | Hon. Renee Marie Bumb | Exelon® Patch (rivastigmine transdermal system or extended release film) |
6,316,023
6,335,031
|
| Allergan Sales, LLC v. Aurobindo Pharma Ltd., 15-1719 (E.D. Tex.) | Nov. 6, 2015 | Hon. Rodney Gilstrap | Acular LS® (ketorolac tromethamine ophthalmic solution) |
8,008,338
8,207,215
8,377,982
8,541,463
8,648,107
8,906,950
8,946,281
|
| Warner Chilcott (US), LLC v. Mylan Pharms., Inc., 15-1740 (E.D. Tex.) | Nov. 9, 2015 | Hon. Rodney Gilstrap | Delzicol® (mesalamine delayed-release capsules) | 6,649,180 |
| Shire Pharm. Development Inc. v. Lupin Ltd., 15-3437 (D. Md.) | Nov. 10, 2015 | Hon. George Jarrod Hazel | Lialda® (mesalamine delayed-release tablets) | 6,773,720 |
| Dexcel Pharma Technologies Ltd. v. Apotex Corp., 15-8010 (D.N.J.) | Nov. 10, 2015 | Hon. Susan D. Wigenton | Omeprazole delayed-release tablets |
9,023,391
7,255,878
|
| Dexcel Pharma Technologies Ltd. v. Sun Pharma Global FZE, 15-8017 (D.N.J.) | Nov. 11, 2015 | Hon. Susan D. Wigenton | Omeprazole delayed-release tablets |
9,023,391
7,255,878
|
| Par Pharm., Inc. v. Breckenridge Pharm., Inc., 15-1039 (D. Del.) | Nov. 11, 2015 | Hon. Sue L. Robinson | Megace® ES (megestrol acetate oral suspension) |
9,101,540
9,101,549
9,107,827
|
| AstraZeneca LP v. HEC Pharm Co., Ltd., 15-1041 (D. Del.) | Nov. 12, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
7,265,124
8,425,934
|
| AstraZeneca LP v. Hisun Pharm. (Hangzhou) Co., Ltd., 15-1042 (D. Del.) | Nov. 12, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) | 8,425,934 |
| Cephalon, Inc. v. Aurobindo Pharma Ltd., 15-1044 (D. Del.) | Nov. 12, 2015 | Hon. Gregory M. Sleet | Nuvigil® (armodafinil tablets) | 7,132,570 |
| Shire Development LLC v. Apotex, Inc., 15-1045 (D. Del.) | Nov. 12, 2015 | Hon. Leonard P. Stark | Fosrenol® (lanthanum carbonate tablets) |
5,968,976
7,381,428
7,465,465
|
| Dexcel Pharma Technologies Ltd. v. Dr. Reddy’s Labs., Ltd., 15-8042 (D.N.J.) | Nov. 12, 2015 | Hon. Susan D. Wigenton | Omeprazole delayed-release tablets |
9,023,391
7,255,878
|
| Graybar Pharms., LLC v. Pozen, Inc., IPR2016-00191 (PTAB) | Nov. 12, 2015 | N/A | Treximet® (naproxen sodium / sumatriptan succinate tablets) | 7,332,183 |
| Cosmo Technologies Ltd. v. Actavis Labs. FL, Inc., 15-1046 (D. Del.) | Nov. 13, 2015 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) | 9,132,093 |
| Cosmo Technologies Ltd. v. Alvogen Pine Brook, LLC, 15-1047 (D. Del.) | Nov. 13, 2015 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) | 9,132,093 |
| Cosmo Technologies Ltd. v. Lupin Ltd., 15-1048 (D. Del.) | Nov. 13, 2015 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) | 9,132,093 |
| Cosmo Technologies Ltd. v. Par Pharm., Inc., 15-1049 (D. Del.) | Nov. 13, 2015 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) | 9,132,093 |
| Novartis Pharms. Corp. v. Par Pharm., Inc., 15-1050 (D. Del.) | Nov. 13, 2015 | Hon. Richard G. Andrews | Afinitor® (everolimus tablets) | 8,436,010 |
| Indivior Inc. v. Sandoz Inc., 15-1051 (D. Del.) | Nov. 13, 2015 | Hon. Richard G. Andrews | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) |
8,475,832
8,017,150
8,603,514
|
| AstraZeneca LP v. HEC Pharm Co., Ltd., 15-8082 (D.N.J..) | Nov. 13, 2015 | Hon. Peter G. Sheridan | Brilinta® (ticagrelor tablets) |
7,265,124
8,425,934
|
| AstraZeneca LP v. Amneal Pharms. LLC, 15-1056 (D. Del.) | Nov. 16, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
6,251,910
6,525,060
7,250,419
7,265,124
8,425,934
|
| AstraZeneca LP v. Prinston Pharm. Inc., 15-1057 (D. Del.) | Nov. 16, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
6,251,910
6,525,060
7,250,419
7,265,124
8,425,934
|
| AstraZeneca LP v. Apotex Inc., 15-1058 (D. Del.) | Nov. 16, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
6,525,060
7,250,419
7,265,124
8,425,934
|
| Merck, Sharp & Dohme Corp. v. Hetero USA Inc., 15-8099 (D.N.J.) | Nov. 16, 2015 | Hon. Claire C. Cecchi | Sustiva® (efavirenz tablets) |
6,639,071
6,939,964
|
| Osi Pharms., LLC v. Breckenridge Pharm., Inc., 15-1063 (D. Del.) | Nov. 17, 2015 | Hon. Sue L. Robinson | Tarceva® (erlotinib hydrochloride tablets) |
RE41,065
6,900,221
|
| Helsinn Healthcare S.A. v. Qilu Pharm. Co., Ltd., 15-8132 (D.N.J.) | Nov. 17, 2015 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride for injection) |
7,947,724
8,729,094
9,066,980
9,173,942
|
| Pfizer Inc. v. Dr. Reddy’s Labs., Ltd., 15-1067 (D. Del.) | Nov. 18, 2015 | Hon. Gregory M. Sleet | Toviaz® (fesoterodine fumarate extended-release tablets) |
6,858,650
7,384,980
7,855,230
7,985,772
8,338,478
|
| Vanda Pharms. Inc. v. Lupin Ltd., 15-1073 (D. Del.) | Nov. 19, 2015 | Hon. Gregory M. Sleet | Fanapt® (iloperidone tablets) |
8,586,610
9,138,432
|
| Cephalon, Inc. v. Fresenius Kabi USA, LLC, 15-1074 (D. Del.) | Nov. 19, 2015 | Hon. Sue L. Robinson | Trisenox® (arsenic trioxide injection) |
6,723,351
6,855,339
6,861,076
6,884,439
|
| Valeant Pharms. Int’l, Inc. v. Mylan Pharms., Inc., 15-8180 (D.N.J.) | Nov. 19, 2015 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide injection) |
8,247,425
8,420,663
8,552,025
8,822,490
|
| Pfizer Inc. v. Dr. Reddy’s Labs., Ltd., 15-8226 (D.N.J.) | Nov. 19, 2015 | Hon. Renee Marie Bumb | Toviaz® (fesoterodine fumarate extended-release tablets) |
6,858,650
7,384,980
7,855,230
7,985,772
8,338,478
|
| AstraZeneca AB v. Dr. Reddy’s Labs., Inc., 15-8267 (D.N.J.) | Nov. 19, 2015 | Hon. Mary L. Cooper | Nexium 24HR® (esomeprazole magnesium delayed-release capsules) |
6,369,085
7,411,070
|
| Mylan Pharms. Inc. v. Baxter Int’l Inc., IPR2016-00217 (PTAB) | Nov. 19, 2015 | N/A | Brevibloc® (esmolol hydrochloride injection) | 6,310,094 |
| Mylan Pharms. Inc. v. Baxter Int’l Inc., IPR2016-00218 (PTAB) | Nov. 19, 2015 | N/A | Brevibloc® (esmolol hydrochloride injection) | 6,528,540 |
| Purdue Pharma L.P. v. Alvogen Pine Brook LLC, 15-1077 (D. Del.) | Nov. 20, 2015 | Hon. Sue L. Robinson | Butrans® (buprenorphine transdermal system) |
RE41,408
RE41,489
RE41,571
|
| Shire LLC v. Abhai, LLC, 15- (D. Mass.) | Nov. 20, 2015 | Hon. William G. Young | Adderall XR® (amphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate extended-release capsules) |
RE42,096
RE41,148
|
| Forest Labs., LLC v. InvaGen Pharms. Inc., 15-1078 (D. Del.) | Nov. 23, 2015 | Hon. Gregory M. Sleet | Viibryd® (vilazodone hydrochloride tablets) |
7,834,020
8,193,195
8,236,804
8,673,921
|
| Jazz Pharms., Inc. v. Sun Pharm. Indus. Ltd., 15-8229 (D.N.J.) | Nov. 23, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 9,050,302 |
| Argentum Pharms. LLC v. Research Corp. Technologies, Inc., IPR2016-00204 (PTAB) | Nov. 23, 2015 | N/A | Vimpat® (lacosamide) | RE38,551 |
| Horizon Pharma, Inc. v. Actavis Labs. Fl., Inc. 15-8523 (D.N.J.) | Nov. 24, 2015 | Hon. Mary L. Cooper | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) |
6,926,907
8,557,285
|
| Horizon Pharma, Inc. v. Actavis Labs. Fl., Inc. 15-8524 (D.N.J.) | Nov. 24, 2015 | Hon. Mary L. Cooper | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) |
8,852,636
8,858,996
8,865,190
|
| Neptune Generics, LLC v. Eli Lilly & Co., IPR2016-00237 (PTAB) | Nov. 24, 2015 | N/A | Alimta® (pemetrexed disodium injection) | 7,772,209 |
| Neptune Generics, LLC v. Eli Lilly & Co., IPR2016-00240 (PTAB) | Nov. 24, 2015 | N/A | Alimta® (pemetrexed disodium injection) | 7,772,209 |
| J. Kyle Bass v. Alpex Pharma., IPR2016-00245 (PTAB) | Nov. 24, 2015 | N/A | Suprenza® (phentermine hydrochloride tablets) | 8,440,170 |
| Symed Labs Ltd. v. Roxane Labs., Inc., 15-8304 (D.N.J.) | Nov. 25, 2015 | Hon. Claire C. Cecchi | Form III Linezolid (linezolid oral suspension) |
7,714,128
7,732,597
7,718,800
7,718,799
|
| Otsuka Pharm. Co., Ltd. v. Alkem Labs. Ltd., 15-8305 (D.N.J.) | Nov. 25, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
8,017,615
8,580,796
8,642,760
|
| Symed Labs Ltd. v. Glenmark Pharms. Inc., USA, 15-8306 (D.N.J.) | Nov. 25, 2015 | Hon. Claire C. Cecchi | Form III Linezolid (linezolid oral suspension) |
7,714,128
7,732,597
|
| Symed Labs Ltd. v. Amneal Pharms. LLC, 15-8307 (D.N.J.) | Nov. 25, 2015 | Hon. Claire C. Cecchi | Form III Linezolid (linezolid oral suspension) |
7,714,128
7,732,597
7,718,800
7,718,799
|
| Supernus Pharms., Inc. v. Actavis Inc., 15-8342 (D.N.J.) | Nov. 25, 2015 | Hon. Renee Marie Bumb | Oxtellar XR® (oxcarbazepine extended-release tablets) | 9,119,791 |
| J. Kyle Bass v. Fresenius Kabi USA, LLC, IPR2016-00254 (PTAB) | Nov. 25, 2015 | N/A | Diprivan® (propofol injection) | 8,476,010 |
| Shire Orphan Therapies LLC v. Fresenius Kabi USA, LLC, 15-1102 (D. Del.) | Nov. 30, 2015 | Hon. Gregory M. Sleet | Firazyr® (icatibant acetate) | 5,648,333 |
| Novartis Pharms. Corp. v. Shilpa Medicare Ltd., 15-1111 (D. Del.) | Nov. 30, 2015 | Hon. Leonard P. Stark | Gleevec® (imatinib mesylate tablets) |
6,894,051
RE43,932
|
| Valeant Pharms. Int’l, Inc. v. Actavis LLC, 15-8353 (D.N.J.) | Nov. 30, 2015 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide injection) |
8,247,425
8,420,663
8,552,025
8,822,490
|
| Helsinn Healthcare S.A. v. Qilu Pharm. Co., Ltd., 15-6392 (E.D. Pa.) | Dec. 1, 2015 | Hon. Cynthia M. Rufe | Aloxi® (palonosetron hydrochloride for injection) |
7,947,724
8,729,094
9,066,980
9,173,942
|
| Unimed Pharms., LLC v. Sandoz Inc., 15-1120 (D. Del.) | Dec. 3, 2015 | Hon. Richard G. Andrews | AndroGel® (testosterone gel) |
6,503,894
8,466,136
8,466,137
8,466,138
8,486,925
8,729,057
8,741,881
8,754,070
8,759,329
9,125,816
9,132,089
|
| Teva Pharms. USA, Inc. v. RB Pharms. Ltd., IPR2016-00280 (PTAB) | Dec. 3, 2015 | N/A | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) | 8,475,832 |
| Teva Pharms. USA, Inc. v. MonSol Rx, LLC, IPR2016-00281 (PTAB) | Dec. 3, 2015 | N/A | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) | 8,603,514 |
| Teva Pharms. USA, Inc. v. MonoSol RX, LLC, IPR2016-00282 (PTAB) | Dec. 3, 2015 | N/A | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) | 8,017,150 |
| UCB, Inc. v. InvaGen Pharms., Inc., 15-6919 (E.D.N.Y.) | Dec. 4, 2015 | Hon. Kiyo A. Matsumoto | Zyrtec-D® (cetirizine hydrochloride / pseudoephedrine hydrochloride tablets) |
6,469,009
7,014,867
7,226,614
|
| Galderma Labs., L.P. v. Teligent, Inc., 15-3876 (N.D. Tex.) | Dec. 4, 2015 | Hon. David C. Godbey | Clobex® (clobetasol propionate topical solution) | 6,106,848 |
| Lupin Ltd. v. Horizon Therapeutics, Inc., IPR2016-00283 (PTAB) | Dec. 4, 2015 | N/A | Ravicti® (glycerol phenylbutyrate oral liquid) | 8,642,012 |
| Lupin Ltd. v. Horizon Therapeutics, Inc., IPR2016-00284 (PTAB) | Dec. 4, 2015 | N/A | Ravicti® (glycerol phenylbutyrate oral liquid) | 8,404,215 |
| Amerigen Pharms. Ltd. v. Janssen Oncology, Inc, IPR2016-00286 (PTAB) | Dec. 4, 2015 | N/A | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
| Takeda Gmbh v. Apotex Corp., 15-8492 (D.N.J.) | Dec. 7, 2015 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) | 5,712,298 |
| AstraZeneca Pharms. LP v. Amneal Pharms. LLC, 15-1139 (D. Del.) | Dec. 9, 2015 | Hon. Gregory M. Sleet | Byetta® (exenatide injection) |
6,872,700
6,902,744
|
| Unimed Pharms., LLC v. Dr. Reddy’s Labs., Ltd., 15-1142 (D. Del.) | Dec. 10, 2015 | Hon. Richard G. Andrews | AndroGel® (testosterone gel) |
6,503,894
8,466,136
8,466,137
8,466,138
8,486,925
8,729,057
8,741,881
8,754,070
8,759,329
9,125,816
9,132,089
|
| Celgene Corp. v. Teva Pharms. USA, Inc., 15-1143 (D. Del.) | Dec. 10, 2015 | Hon. Richard G. Andrews | Istodax® (romidepsin injection) |
7,608,280
7,611,724
|
| Aptalis Pharma US, Inc. v. Pharm. Sourcing Partners, Inc., 15-8637 (D.N.J.) | Dec. 14, 2015 | Hon. Mary L. Cooper | Canasa® (mesalamine rectal suppositories) |
7,541,384
8,217,083
8,436,051
|
| Sandoz Inc. v. Eli Lilly & Co., IPR2016-00318 (PTAB) | Dec. 14, 2015 | N/A | Alimta® (pemetrexed disodium injection) | 7,772,209 |
| Purdue Pharma L.P. v. Amneal Pharms. LLC, 15-1152 (D. Del.) | Dec. 15, 2015 | Hon. Sue L. Robinson | OxyContin® (oxycodone extended-release tablets) |
7,674,799
7,674,800
7,683,072
8,114,383
8,309,060
8,337,888
8,808,741
8,894,987
8,894,988
9,060,976
9,034,376
9,073,933
|
| Helsinn Healthcare S.A. v. Dr. Reddy’s Labs., Ltd., 15-8662 (D.N.J.) | Dec. 15, 2015 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride for injection) | 9,173,942 |
| Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 15-8663 (D.N.J.) | Dec. 15, 2015 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride for injection) | 9,173,942 |
| Purdue Pharma L.P. v. Mylan Pharms. Inc., 15-1155 (D. Del.) | Dec. 16, 2015 | Hon. Sue L. Robinson | OxyContin® (oxycodone extended-release tablets) | 9,073,933 |
| Alcon Research Ltd. v. Watson Labs., Inc., 15-1159 (D. Del.) | Dec. 16, 2015 | Hon. Sue L. Robinson | Pazeo® (olopatadine hydrochloride ophthalmic solution) | 8,791,154 |
| Sanofi-Aventis U.S. LLC v. Amylin Pharms., LLC, IPR2016-00348 (PTAB) | Dec. 16, 2015 | N/A | Byetta® (exenatide injection) | 7,297,761 |
| Sanofi-Aventis U.S. LLC v. Amylin Pharms., LLC, IPR2016-00353 (PTAB) | Dec. 16, 2015 | N/A | Byetta® (exenatide injection) | 7,691,963 |
| Sanofi-Aventis U.S. LLC v. Amylin Pharms., LLC, IPR2016-00354 (PTAB) | Dec. 16, 2015 | N/A | Byetta® (exenatide injection) | 8,445,647 |
| Sanofi-Aventis U.S. LLC v. Amylin Pharms., LLC, IPR2016-00355 (PTAB) | Dec. 16, 2015 | N/A | Byetta® (exenatide injection) | 8,951,962 |
| Shire Orphan Therapies LLC v. Sandoz Inc., 15-1161 (D. Del.) | Dec. 17, 2015 | Hon. Gregory M. Sleet | Firazyr® (icatibant acetate) | 5,648,333 |
| Bayer Healthcare LLC v. Mylan Pharms. Inc., 15-1162 (D. Del.) | Dec. 17, 2015 | Hon. Leonard P. Stark | Nexavar® (sorafenib tosylate tablets) |
7,897,623
7,235,576
7,351,834
8,877,933
8,841,330
|
| Cubist Pharms. LLC v. Sagent Pharms., Inc., 15-1164 (D. Del.) | Dec. 17, 2015 | Hon. Gregory M. Sleet | Cubicin® (daptomycin for injection) |
6,468,967
6,852,689
8,058,238
8,129,342
|
| Purdue Pharma L.P. v. Mylan Pharms. Inc., 15-0232 (D. Del.) | Dec. 17, 2015 | Hon. Irene M. Keeley | OxyContin® (oxycodone extended-release tablets) | 9,073,933 |
| Forest Labs., LLC v. Panacea Biotec, Ltd., 15-1171 (D. Del.) | Dec. 18, 2015 | Hon. Leonard P. Stark | Namenda® XR (memantine hydrochloride extended-release tablets) |
8,168,209
8,173,708
8,283,379
8,329,752
8,362,085
8,598,233
|
| Lower Drug Prices for Consumers, LLC v. Forest Labs. Holdings, Ltd., IPR2016-00379 (PTAB) | Dec. 22, 2015 | N/A | Bystolic® (nebivolol hydrochloride tablets) | 6,545,040 |
| Recro Gainesville LLC v. Actavis Labs. FL, Inc., 15-1196 (D. Del.) | Dec. 23, 2015 | Hon. Gregory M. Sleet | Zohydro® ER (hydrocodone bitartrate extended-release capsules) | 9,132,096 |
| Sanofi v. Alkem Labs. Ltd., 15-1200 (D. Del.) | Dec. 23, 2015 | Hon. Richard G. Andrews | Multaq® (dronedarone hydrochloride tablets) | 9,107,900 |
| Sanofi v. First Time US Generics LLC, 15-1205 (D. Del.) | Dec. 23, 2015 | Hon. Richard G. Andrews | Multaq® (dronedarone hydrochloride tablets) | 9,107,900 |
| Sanofi v. Glenmark Pharms. Inc. USA, 15-1206 (D. Del.) | Dec. 23, 2015 | Hon. Richard G. Andrews | Multaq® (dronedarone hydrochloride tablets) | 9,107,900 |
| Sanofi v. Sandoz Inc., 15-1207 (D. Del.) | Dec. 23, 2015 | Hon. Richard G. Andrews | Multaq® (dronedarone hydrochloride tablets) | 9,107,900 |
| Sanofi v. Sun Pharma Global FZE, 15-1208 (D. Del.) | Dec. 23, 2015 | Hon. Richard G. Andrews | Multaq® (dronedarone hydrochloride tablets) | 9,107,900 |
| Sanofi v. Watson Labs., Inc., 15-1209 (D. Del.) | Dec. 23, 2015 | Hon. Richard G. Andrews | Multaq® (dronedarone hydrochloride tablets) | 9,107,900 |
| Otsuka Pharm. Co., Ltd. v. Ajanta Pharma Ltd., 15-8830 (D.N.J.) | Dec. 23, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
| Aptalis Pharma US, Inc. v. Delcor Asset Corp., 15-8919 (D.N.J.) | Dec. 23, 2015 | Hon. Mary L. Cooper | Canasa® (mesalamine rectal suppositories) |
7,541,384
8,217,083
8,436,051
|
| Aptalis Pharma US, Inc. v. Delcor Asset Corp., 15-1210 (D. Del.) | Dec. 27, 2015 | Hon. Leonard P. Stark | Canasa® (mesalamine rectal suppositories) |
7,541,384
8,217,083
8,436,051
|
| Lupin Ltd. v. iCeutica Pty Ltd., IPR2016-00397 (PTAB) | Dec. 28, 2015 | N/A | Zorvolex® (diclofenac tablets) | 8,999,387 |
| Lupin Ltd. v. iCeutica Pty Ltd., IPR2016-00399 (PTAB) | Dec. 28, 2015 | N/A | Zorvolex® (diclofenac tablets) | 9,017,721 |
| Cubist Pharms. LLC v. Actavis LLC, 15-1214 (D. Del.) | Dec. 29, 2015 | Hon. Gregory M. Sleet | Cubicin® (daptomycin for injection) |
6,468,967
6,852,689
8,058,238
8,129,342
|
| Novartis Pharms. Corp. v. Actavis, Inc., 15-1219 (D. Del.) | Dec. 30, 2015 | Hon. Richard G. Andrews | Jadenu® (deferasirox tablets) | 6,465,504 |
| Otsuka Pharm. Co., Ltd. v. Intas Pharms. Ltd., 15-8955 (D.N.J.) | Dec. 30, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
| Novartis Pharms. Corp. v. Actavis, Inc., 15-8978 (D.N.J.) | Dec. 31, 2015 | Hon. Jose L. Linares | Jadenu® (deferasirox tablets) | 6,465,504 |
| Merz Pharms., LLC v. Taro Pharms. U.S.A., Inc., 15-10168 (S.D.N.Y.) | Dec. 31, 2015 | Hon. William H. Pauley, III | Naftin® (naftifine hydrochloride gel) | 9,161,914 |
GENERICally Speaking Winter 2015
Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.